Kevin Kunzmann, Michael J Grayling, Kim May Lee, David S Robertson, Kaspar Rufibach, James M S Wason
{"title":"贝叶斯观点对确证试验样本大小推导的回顾。","authors":"Kevin Kunzmann, Michael J Grayling, Kim May Lee, David S Robertson, Kaspar Rufibach, James M S Wason","doi":"10.1080/00031305.2021.1901782","DOIUrl":null,"url":null,"abstract":"<p><p>Sample size derivation is a crucial element of planning any confirmatory trial. The required sample size is typically derived based on constraints on the maximal acceptable Type I error rate and minimal desired power. Power depends on the unknown true effect and tends to be calculated either for the smallest relevant effect or a likely point alternative. The former might be problematic if the minimal relevant effect is close to the null, thus requiring an excessively large sample size, while the latter is dubious since it does not account for the a priori uncertainty about the likely alternative effect. A Bayesian perspective on sample size derivation for a frequentist trial can reconcile arguments about the relative a priori plausibility of alternative effects with ideas based on the relevance of effect sizes. Many suggestions as to how such \"hybrid\" approaches could be implemented in practice have been put forward. However, key quantities are often defined in subtly different ways in the literature. Starting from the traditional entirely frequentist approach to sample size derivation, we derive consistent definitions for the most commonly used hybrid quantities and highlight connections, before discussing and demonstrating their use in sample size derivation for clinical trials.</p>","PeriodicalId":50801,"journal":{"name":"American Statistician","volume":" ","pages":"424-432"},"PeriodicalIF":1.8000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7612172/pdf/","citationCount":"0","resultStr":"{\"title\":\"A Review of Bayesian Perspectives on Sample Size Derivation for Confirmatory Trials.\",\"authors\":\"Kevin Kunzmann, Michael J Grayling, Kim May Lee, David S Robertson, Kaspar Rufibach, James M S Wason\",\"doi\":\"10.1080/00031305.2021.1901782\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Sample size derivation is a crucial element of planning any confirmatory trial. The required sample size is typically derived based on constraints on the maximal acceptable Type I error rate and minimal desired power. Power depends on the unknown true effect and tends to be calculated either for the smallest relevant effect or a likely point alternative. The former might be problematic if the minimal relevant effect is close to the null, thus requiring an excessively large sample size, while the latter is dubious since it does not account for the a priori uncertainty about the likely alternative effect. A Bayesian perspective on sample size derivation for a frequentist trial can reconcile arguments about the relative a priori plausibility of alternative effects with ideas based on the relevance of effect sizes. Many suggestions as to how such \\\"hybrid\\\" approaches could be implemented in practice have been put forward. However, key quantities are often defined in subtly different ways in the literature. Starting from the traditional entirely frequentist approach to sample size derivation, we derive consistent definitions for the most commonly used hybrid quantities and highlight connections, before discussing and demonstrating their use in sample size derivation for clinical trials.</p>\",\"PeriodicalId\":50801,\"journal\":{\"name\":\"American Statistician\",\"volume\":\" \",\"pages\":\"424-432\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2021-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7612172/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"American Statistician\",\"FirstCategoryId\":\"100\",\"ListUrlMain\":\"https://doi.org/10.1080/00031305.2021.1901782\",\"RegionNum\":4,\"RegionCategory\":\"数学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2021/4/22 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"STATISTICS & PROBABILITY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Statistician","FirstCategoryId":"100","ListUrlMain":"https://doi.org/10.1080/00031305.2021.1901782","RegionNum":4,"RegionCategory":"数学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/4/22 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"STATISTICS & PROBABILITY","Score":null,"Total":0}
引用次数: 0
摘要
样本量的确定是计划任何确证试验的关键因素。所需样本量通常是根据可接受的最大 I 类错误率和最小期望功率的限制条件得出的。作用力取决于未知的真实效应,往往根据最小相关效应或可能的点替代效应来计算。如果最小相关效应接近于空值,前者可能会有问题,因此需要过大的样本量,而后者则值得怀疑,因为它没有考虑到可能的替代效应的先验不确定性。从贝叶斯的角度来推导频数试验的样本量,可以调和替代效应的相对先验可信性与基于效应大小相关性的观点。关于如何在实践中采用这种 "混合 "方法,已经提出了许多建议。然而,文献中对关键量的定义往往存在微妙的差异。我们从传统的完全频数主义的样本量推导方法出发,推导出最常用的混合量的一致定义并强调其联系,然后讨论并演示它们在临床试验样本量推导中的应用。
A Review of Bayesian Perspectives on Sample Size Derivation for Confirmatory Trials.
Sample size derivation is a crucial element of planning any confirmatory trial. The required sample size is typically derived based on constraints on the maximal acceptable Type I error rate and minimal desired power. Power depends on the unknown true effect and tends to be calculated either for the smallest relevant effect or a likely point alternative. The former might be problematic if the minimal relevant effect is close to the null, thus requiring an excessively large sample size, while the latter is dubious since it does not account for the a priori uncertainty about the likely alternative effect. A Bayesian perspective on sample size derivation for a frequentist trial can reconcile arguments about the relative a priori plausibility of alternative effects with ideas based on the relevance of effect sizes. Many suggestions as to how such "hybrid" approaches could be implemented in practice have been put forward. However, key quantities are often defined in subtly different ways in the literature. Starting from the traditional entirely frequentist approach to sample size derivation, we derive consistent definitions for the most commonly used hybrid quantities and highlight connections, before discussing and demonstrating their use in sample size derivation for clinical trials.
期刊介绍:
Are you looking for general-interest articles about current national and international statistical problems and programs; interesting and fun articles of a general nature about statistics and its applications; or the teaching of statistics? Then you are looking for The American Statistician (TAS), published quarterly by the American Statistical Association. TAS contains timely articles organized into the following sections: Statistical Practice, General, Teacher''s Corner, History Corner, Interdisciplinary, Statistical Computing and Graphics, Reviews of Books and Teaching Materials, and Letters to the Editor.